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Geldanamycin (GA) is a benzoquinone-containing ansamycin that inhibits heat shock protein 90. GA derivatives are being
evaluatedasanti-neoplasticagents,buttheirutilityagainstparasiteswhoseheatshockproteins (Hsps)havehomologywithhuman
Hsp90 is unknown. The activities of four synthetic GA derivatives were tested in vitro using adult Brugia malayi and Schistosoma
japonicum. Two of the derivatives, 17-N-allyl-17-demethoxygeldanamycin (17-AAG) and 17-N-(2-dimethylaminoethylamino)-
17-demethoxygeldanamycin (DMAG), are currently in human clinicaltrials as anticancer drugs. Using concentrations considered
safe peak plasma concentrations for these two derivatives, all four derivatives were active against both parasites. The less toxic
derivative 17-AAGwasaseﬀective asGA inkillingS.japonicum,a n db o t hD M A Ga n d5  -bromogeldanoxazinonewere moreactive
than17-AAGagainstB. malayi. Thiswork supports continued evaluationofansamycinderivatives asbroad spectrum antiparasitic
agents.
1.Introduction
Heat shock proteins (Hsps) play critical roles in diverse
biological processes including cellular development and
homeostasis. Heat shock protein 90 (Hsp90) is an abundant
and important eukaryotic cytosolic ATP-binding protein
that serves as a chaperone in cellular processes including
apoptosis and proliferation [1, 2]. Geldanamycin (GA; 1 in
Figure 1) is a naturally occurring benzoquinone ansamycin,
originally isolated from Streptomyces hygroscopicus [3]. GA
binds to the ATP-binding pocket of Hsp90, speciﬁcally
inhibiting ATPase activity [4, 5] and therefore it has been
evaluated for its antiproliferative eﬀects in oncogenesis in
vitro and in vivo with promising application as a novel anti-
cancer therapy [6, 7]. Several laboratories have reported
activity of GA against the Hspof Plasmodium falciparum and
Brugia pahangi; however other nematodes with conserved
Hsp such as Caenorhabditis elegans are not aﬀected by
GA, suggesting possible conformational heterogeneity of
Hsp between species [8, 9]. A less toxic derivative of
geldanamycin, 17-N-allyl-17-demethoxygeldanamycin [10]
(17-AAG; 2 in Figure 1), is now in phase II clini-
cal trials [11, 12] in humans with neoplastic disorders.
Phase I trials with 17-AAG showed safety proﬁles for
dosing schedules with peak plasma concentrations of
ca. 10µM[ 13–15]. A second 17-amino-substituted gel-
danamycin derivative, 17-N-(2-dimethylaminoethylamino)-
17-demethoxygeldanamycin (DMAG; 3 in Figure 1), is now
undergoing phase I clinical trials [16]. However, neither
of these compounds is currently widely available to test
their spectrum of activity against human parasites. In the
Philippines, two of the World Health Organization’s top
ten neglected tropical parasitic diseases, lymphatic ﬁlariasis
(B. malayi or W. bancrofti) and schistosomiasis caused by
Schistosoma japonicum, account for hundreds of thousands
of patient illnesses each year. Therefore, in the course of2 Journal of Parasitology Research
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Figure 1: Geldanamycin (GA) chemical structure and structures and synthesis of four derivatives.
research to discover new classes of antiparasitic compounds,
we studied the in vitro response of adult B. malayi and S.
japonicum to 17-AAG and 17-DMAG.
2.MaterialandMethods
2.1. Geldanamycin Derivatives 2–5 Preparation. 17-N-
Allylamino-17-demethoxygeldanamycin [17-AAG, (2)],
and 17-N-(2-dimethylaminoethylamino)-17-demethoxy-
geldanamycin[17-DMAG,(3)],17-(N-azetidinyl)-17-deme-
thoxygeldanamycin (4) were made in essentially quantitative
yield by room temperature reaction of geldanamycin (1)
with the appropriate primary or cyclic secondary amine
and 5 -bromogeldanoxazinone (5) was made in moderate
yield (60% yield) by heating geldanamycin with 2-amino-
5-bromophenol in the presence of acetic acid [17–20]( s e e
Figure 1).
2.2. Parasite Materials. Adult B. malayi were obtained from
the laboratory of Dr. Ray Kaplan (FR3 facility, Athens,
Georgia) and maintained in 12-well ﬂat bottomed plates
containing RPMI medium with penicillin-streptomycin and
0.5% DMSO at 37◦C with humidity and 5% CO2.M a t u r e
male and female S. japonicum were obtained following per-
cutaneous infection of BALB/C mice with 40 cercariae, iso-
lated from S. japonicum ﬁeld-infected Oncomelania quadrasi
in the Philippines, and subsequent sacriﬁce of the mice at
day 35 to collect mature male and female worms by saline
perfusion of the mesenteric vasculature using a ﬁne-gauged
butterﬂy needle attached to a 50-ml sterile syringe ﬁlled with
sterile normal saline.
2.3. Assay of Drug Toxicity. The eﬀect of test compounds
on adult B. malayi was monitored at ﬁnal concentrations of
0.5µM, 1µM, 5µM, 0µM, 25µM. Filarial death was assessed
by determining the time required for complete nonreversible
cessation of motility. Each assay well contained 3 adult
worms, and assays were conductedin triplicate. Experiments
in triplicate were repeated at least six times. Negative control
wells contained adult parasites cultured in media alone andJournal of Parasitology Research 3
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Figure 2: (a).Survival of paired adult male andfemale Schistosomajaponicum in the presence of humanred blood cells and ﬁve micromolar
geldanamycin(GA,triangles)orﬁvemicromolar17-AAG(squares)compared tocontrolparasitessupplemented onlywithhumanred blood
cells (diamonds).50%–60%mortalitywasachieved at24hours while90%ofcontrols remained viable(P<. 001).(b).Survival ofindividual
male worms. 50%–60% mortality was achieved at 24 hours while 90% of controls remained viable (P<. 001). (c). Survival of individual
female worms. 35%–50% mortality at 24 hours while 95% of controls remained viable (P<. 001). At 72 hours 17-AAG and GA caused
50% greater mortality versus controls. D. Survival of individual male and female worms cultured together. GA, male, star. GA female, circle.
17-AAG male, triangle. 17-AAG female, cross. At 36 hours GA caused 60% mortality in male worms while 90% of controls remained viable
(P<. 001). At 72 hours 90%–100% of GA and 17-AAG treated worms were dead versus 50% mortality in controls (P<. 001). For (a)–(d),
the data represent the mean ± S.D. of triplicate determinations in a representative experiment.
positive control wells additionally contained 100µMa l b e n -
dazole. Under these conditions, negative control parasites
remained actively motile for 500 hours (∼20 days), whereas
albendazole killed 100% of the ﬁlaria within 384 hours
(16 days). Statistically signiﬁcant diﬀerences in killing times
were deﬁned as P values <.01 (students t-test). Under these
conditions, nonreversible cessation of motility corresponded
to parasite death as measured by the MTT uptake assay.
For testing of drug toxicity on S. japonicum,ﬁ v ew o r m
pairs, ﬁve male and ﬁve female worms were placed into
each well of a 24-well ﬂat bottom plate containing 5µM
of either GA or 17-AAG with 2mL complete RPMI-16404 Journal of Parasitology Research
media supplemented with human red blood cells, 2g/L
glucose, 0.3g/L L-glutamine, 2.0g/L NaHCO3, 15% fetal
bovine serum (heat inactivated), and 5% pen/strep (10,000
units penicillin and 10mg/streptomycin in 0.9%NaCl).
Assays were performed in triplicate and incubated in a
humidiﬁed 5% CO2 chamber at 37◦C. The physical activity
of parasites (e.g., feeding behavior, movement, and viability)
was recorded after 12, 15, 18, 24, 26, 48, 60, and 72 hours.
Fresh culture media and test compounds were added after 18
and 36 hours. These experiments were all repeated at least
ﬁve times. Experiments were repeated using paired male and
female worms, as well as individual male worms and female
worms. Eﬀects of GA derivatives were highly reproducible
using paired adult worms, individual female, and individual
male worms (see Figure 2). Each graphic point represents
three individual experiments.
3.Results
Both GA and 17-AAG killed adult male and female S.
japonicum at a concentration of 5µM( F i g u r e s2(a)–2(d)).
The eﬀects of both compounds were identical using paired
worms, isolated males, isolated females, and isolated larvae
(cercariae, data not shown.) The eﬀects of both compounds
were highly reproducible within 12–24 hours, even though
the longevity of adult S. japonicum cultured in minimal
media is only 40%–50% at 72 hours. Lower concentrations
of each compound were not tested due to a scarcity of adult
S. japonicum.
Adult B. malayi were killed quicker by both GA and
17-AAG and at concentrations signiﬁcantly lower than
100µm of albendazole (positive control) (Figure 3(a)).
Macroﬁlaricidal concentrationsof17-AAGwere 10–20times
lower than the peak plasma concentrations (10µM) that
are reported as safe in phase I clinical trials. All four
GA derivatives were macroﬁlaricidal at 500nM, the lowest
concentration tested (Figure 3(b)). DMAG and compound 4
had the most rapid macroﬁlaricidal eﬀect (9 days) compared
to 100µM albendazole (16 days) under these conditions
(P<. 01 for all concentrations versus albendazole). Most
compounds at concentrations greater than 10µM exhibited
some precipitation in RPMI with 0.5% DMSO.
4.Discussion
Human heat shock protein 90 (Hsp90) belongs to the
“GHKL” group of ATPases [22]. The ATP-binding site
of this group of proteins is uniquely aﬀected by GA.
Molecular chaperones such as Hsps play critical roles in
diverse biological processes including cellular development
and homeostasis. A high degree of conservation of same and
similar amino acid residues is exhibited in the ATP-binding
pocket in the known protein sequences of Hsp90 of various
species (Figure 4). The antiparasitic eﬀect of GA derivatives
suggests that similar life-dependent ATP binding sites are
being aﬀected in such organisms.
TheimportanceofHspsinthebiologyofhumanandvet-
erinary parasites has been reported previously in numerous
genera including Leishmania, Trypanosoma, Plasmodium,
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Figure 3: (a) Eﬀect of Geldanamycin and 17-AAG on adult Brugia
malayi in vitro. 17-AAG killed B. malayi adults faster and at
concentrations two hundred times lower than albendazole (positive
control). Statistically signiﬁcant diﬀerences in rates of killing were
observed for5–100µM GA and17-AAG versus 100µM albendazole
(positive control, P<. 001). 500nM and 1000nM GA and 17-
AAG were equivalent to 100µM albendazole at 280–300 hours. (b)
Eﬀect of 17-AAG compared to three other GA derivatives on adult
B. malayi in vitro. Negative control worms (i.e., no drug) remain
viable for 500 hours and 100µM albendazole kills parasites by 15
days. All three concentrations of the four GA derivatives killed
adult B. malayi faster than 100µM albendazole (positive control,
P<. 001).Numbers aboveeach bar aremeanhours to 100%killing.
Compounds 3 (DMAG) and 5 (5 -bromogeldanoxazinone) were
more active against B. malayi than 17-AAG at 500nM (P<. 001).
All fourcompoundsat each concentrationtested (500nM—10µM)
killed ﬁlarial more quickly than 100µM albendazole (positive
control, P<. 001). For (a) and (b), the data represent the mean
± S.D. of triplicate determinations in a representative experiment.
Schistosoma,andvariousnematodes.Devaneyetal.,reported
macroﬁlaricidal activity of GA against the dog and cat ﬁlaria,
Brugia pahangi, at nanomolar levels [23]. Also, it was noted
thatwhile GAclearlyboundtoB.pahangi Hsp,thefree livingJournal of Parasitology Research 5
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Figure 4: Multiple sequence alignment (Clustal W) of ﬁve eukaryotic and one prokaryotic heat shock proteins (Hsp90). Grey-shaded areas
indicate residues that comprise the geldanamycin-binding pocket that can be conserved across species [4, 21]. S. cerevesiae : Saccharomyces
cerevisiae; E. coli : Escherichia coli; S. japonicum : Schistosoma japonicum; B. malayi : Brugia malayi; C. elegans : Caenorhabditis elegans.
nematode Caenorhabiditis elegans did not bind GA despite
a high degree of conservation between the nematode Hsp
sequences [8]. A recent study of the geldanamycin-binding
ability of Hsp90, derived from a number of nematodes,
found that in contrast to some obligate parasites, the free-
living species and the parasitic species having free-living
environmental larval stages that were tested did not bind
geldanamycin [9]. In the case of P. falciparum, a systems
analysis of chaperone networks combining experimental
interactome, in silico and yeast two hybrid assays, facilitated
predictions and functional assignment for Hsp70-Hsp40
interactions and the Hsp90 and Hsp100 families [24]. In
P. falciparum, GA is known to inhibit all intraerythrocytic
stages and kills the parasites within a single developmental
cycle [25, 26].
The parasite killing assays employed in these studies
diﬀer slightly from those used by other WHO collaborating
groups. For example, ﬁlaria killing studies are sometimes
conductedinthepresenceofmonkeykidneycellfeederlayers
up to a maximum of 120 hours, to control for the toxicity
of test compounds [27] .H o w e v e r ,i nt h ec a s eo fm o s tG A
derivatives tested herein, (1) the lack of toxicity to human
cells was already established, (2) the removal of serum from
culture media permits longer in vitro culture as noted, up to
500 hours, and (3)such serum removal allows the evaluation
of lipophilic compounds which can bind to albumin or
other serum proteins and can obscure their inherent activity
against ﬁlaria [28]. Recent advances in medicinal chemistry
include strategies to make use of lipophilic drugs [29]w h i c h
by themselves could have lower peak plasma concentrations
and greater volumes of distribution.
In the case of schistosomes, WHO collaborating centers
generally use a 5-day assay without red blood cells in
the culture media when evaluating the activity of lead
compounds against S. mansoni and S. hematobium [30].
However, S. japonicum adult worms are much more diﬃcult
to maintain in vitro using the same in vitro conditions used
for S. mansoni.C e r c a r i a e ,ad i ﬀerent life cycle stage of S.
japonicum,a r es i m i l a r l ya ﬀected by GA derivatives as well
(data not shown).6 Journal of Parasitology Research
Antiparasite drug discovery strategies commonly focus
on identiﬁcation of molecular targets unique to the par-
asite in the belief that host toxicity or cross-inhibition of
host pathways will be minimized. While such approaches
m a yu l t i m a t e l yb ee ﬀective, an alternative approach is to
target proteins or pathways that are common to both
parasite and host, but which may have evolved over time
features, domains, or alternative functions that are unique
to the species. When such a molecule is acknowledged as
a rationale target for drug discovery in more than one
disease, this approach has the beneﬁt of a broader base of
scientiﬁc and medicinal chemistry infrastructure on which
to develop lead antiparasite compounds. Additionally, the
ubiquity of such target proteins among parasites allows
parallel development of therapeutics that can be eﬀective
in the treatment of diﬀering parasitic infections. Thus the
next steps in the evaluation of GA derivatives as parasitic
agents must include pharmacokinetic and in vivo killing
experiments to determine eﬀective in vivo dosing regimens
using the S. japonicum mouse model and either the B.
malayi transplanted jird model or the L3-induced B. malayi
infection in Mastomys coucha [31]. Additionally, to be
determined are the degree to which the antiparasitic eﬀect
of GA and its derivatives is dependent on penetration to
target, binding aﬃnity, unique heat shock proteindependent
cochaperones, or possible additional GA targets. Although
the antiﬁlarial activity of various anticancer compounds
obtained from the U.S. National Cancer Institute has been
previously studied, neither GA or its derivatives were so
studied [32]. An alternative strategy for activity evaluation
of compounds against S. japonicum would include a side-to-
side comparison with S. mansoni, which is easier to maintain
in vitro and can demonstrate more easily the in vitro eﬀects
of a positive control drug such as praziquantel [33]. (S.
mansoni, however, does not exist in the Philippines.)
A ﬂuorescence polarization assay for Hsp90 activity was
recentlyreportedbyTaldoneetal.[34].Wholewormextracts
of Brugia pahangi were used in a modiﬁed assay previously
validated for discovery of antitumor Hsp90 inhibitors, and
this assay was validated using soluble B. pahangi extracts.
Though reported suitable for high-throughput screening,
compounds identiﬁed by this in vitro method do not
take into account chemical properties that would facilitate
or inhibit transport of antiparasite compounds across the
cuticle of adult worms. Also, soluble extracts of the human
parasite, B. malayi, were not systematically compared to the
extracts from B. pahangi, an animal parasite.
Although compounds 4 and 5 have not been tested
in humans nor are their pharmacokinetic parameters yet
known, compounds 17-AAG (2)a n dD M A G( 3 )h a v et h e
advantage of having been tested in humans and were
found to be highly active against human tumor cells in
vitro and accordingly were and are being evaluated in
human clinical trials of cancer chemotherapy. The obtained
human safety and tolerance data of the latter two drugs at
concentrations found lethal to S. japonicum and B. malayi
gives added reason for investigation of these and other
Hsp90 inhibitors as antiparasitic therapeutic agents. Addi-
tionally, the recent ﬁnding of the reduced and protonated
hydroquinone version of 17-AAG having water solubility
and equivalent eﬃcacy as a Hsp90 inhibitor allows entr´ e
to similar water soluble analogs of other 17-N-alkylamino-
17-demethoxygeldanamycin derivatives [35]. Modulation of
heat shockproteinsisincreasingly being recognized ashaving
various demonstrated and potential beneﬁcial therapeutic
eﬀects [36]. Our in vitro studies support the activity of GA
derivatives against the Hsp of two important new groups of
human parasites.
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